![The E3 ubiquitin ligase TRIP12 is required for pancreatic acinar cell plasticity and the development of pancreatic cancer.](https://www.crct-inserm.fr/wp-content/uploads/2022/11/cropped-Pancreatic-Cancer-400x245-FR.png)
![The E3 ubiquitin ligase TRIP12 is required for pancreatic acinar cell plasticity and the development of pancreatic cancer.](https://www.crct-inserm.fr/wp-content/uploads/2022/11/cropped-Pancreatic-Cancer-400x245-FR.png)
![An oncolytic virus with strong appetence for the most aggressive type of pancreatic cancer cells](https://www.crct-inserm.fr/wp-content/uploads/2024/04/image-extrait-cordelier-mars-2024.jpg)
An oncolytic virus with strong appetence for the most aggressive type of pancreatic cancer cells
An oncolytic virus with strong appetence for the most aggressive type of pancreatic cancer cells Oncolytic virus, pancreatic cancer, precision medicine Pierre Cordelier – Team ImPact – Therapeutic innovation in pancreatic cancer The Minute virus of mice...![Cytidine deaminase confers resistance to DNA-damaging drugs](https://www.crct-inserm.fr/wp-content/uploads/2024/02/Image2.jpg)
Cytidine deaminase confers resistance to DNA-damaging drugs
Cytidine deaminase confers resistance to DNA-damaging drugs Pancreatic cancer, cytidine deaminase, replication stress, resistance to treatment Pierre Cordelier – Team ImPact – Therapeutic innovation in pancreatic cancer Cytidine deaminase (CDA) plays a...![Focus research 2022 ImPact team](https://www.crct-inserm.fr/wp-content/uploads/2021/09/Imagepageequipecordelier.png)
Focus research 2022 ImPact team
Focus research 2022 ImPact team Pancreatic tumors are notorious for their resistance to immunotherapies. In this context, the ImPACT team has been investigating the therapeutic potential of Toll-like receptor (TLR) agonist molecules, which are expressed in tumors, and...![Preclinical development of non-viral gene therapy for patients with advanced pancreatic cancer](https://www.crct-inserm.fr/wp-content/uploads/2023/03/inserm-57551-microscopeboitecellules-dlargeur.jpg)
Preclinical development of non-viral gene therapy for patients with advanced pancreatic cancer
Preclinical development of non-viral gene therapy for patients with advanced pancreatic cancer Pancreatic cancer, non-viral gene therapy, resistance to treatment, chemotherapy, preclinical regulatory experiments. Pierre Cordelier Team ImPact- Therapeutic innovation in...![Pancreatic cancer cell and gene biotherapies; past, present and future](https://www.crct-inserm.fr/wp-content/uploads/2023/01/cover-1.jpg)